FDA Approved: DIVALPROEX SODIUM — Supplemental Application (BluePoint Laboratories)

View source ↗

Summary

FDA approved a supplemental application for divalproex sodium submitted by BluePoint Laboratories, associated with an existing ANDA.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bipolar Disorder
• Epilepsy
• Migraine

Drugs mentioned

• DIVALPROEX SODIUM (divalproex sodium)

Snippet

SUPPL AP for DIVALPROEX SODIUM (DIVALPROEX SODIUM)